Global Insulin Delivery Devices Market by Product Type (Insulin Pens, Insulin Syringes, Insulin Injectors, Insulin Pumps), By End User (Hospitals & Clinics, Patient/Home Care), by Region (North America, Europe, Asia-pacific, Latin America, Middle East and Africa): Global Forecasts 2017 to 2027

Market Overview:

The Global Insulin Delivery Devices Market was valued US$ 14.3 Bn in 2020 is expected to reach US$ 25.4 Bn by 2027, with a growing CAGR of 8.7% during the forecast period (2021-2027).

Insulin delivery devices are the medical devices that are used to inject insulin externally with the help of pumps, pens, injectors, or syringes. These devices are mostly used when pancreas is unable to produce sufficient insulin in the body. With the help of these devices, insulin is directly released into blood stream to avoid first-pass metabolism. The factors contributing the growth of insulin delivery devices are rising number of diabetic populations across the globe and growth in diabetes contributing factors such as obesity, stress, unhealthy eating and drinking habits, and other environmental factors. Additionally, introduction of new smarter technology and ear of automation boost the growth of insulin delivery devices market.

Insulin Delivery Devices Market
With the increase in technologies and developing perception of patient centric, new approaches related to the insulin delivery are being developed. For instance, insulin that can be inhale, is one of the latest upcoming new ways of delivering insulin and the recent approval for interoperable insulin pump is new buzz word in the insulin delivery devices market. This has inspired the industries for development of more advance insulin delivery devices.

The Global Insulin Delivery Device Market Segmentation:

  • By Product Type
    • Insulin Pens
    • Insulin Syringes
    • Insulin Injectors
    • Insulin Pumps
  • By End User
    • Hospital & Clinic
    • Patient Care/Home Care
  • By Geographical Region
    • North America
    • Europe
    • Asia- Pacific
    • South America
    • Middle East & Africa

Based on product type, insulin pens segment is estimated to grow at the highest CAGR during the forecast period.

Based on product type, the insulin delivery device is broadly segmented in insulin pens, insulin pumps, insulin syringes and insulin injectors. Out of all, insulin pen is expected to show highest market growth of insulin delivery devices during the forecasting period. Insulin pens are easy to carry due to it’s small size and has the provision of refilling and reuse. This led to increase in market growth during the forecast period. Conversely, insulin syringes accounted the largest market share in year 2020. Insulin syringes are easy to use.

Based on End user, patients/home care segment held the largest share of insulin delivery device market in 2020 and it is expected to grow with highest CAGR in coming years.

As compared to hospitals and clinics, patient's care/ home care drives the growth of insulin delivery device market. Administration of insulin is long term medical condition which can be managed by taking medication at home. Insulin device are self-administering devices and provides patient compliance. With an increase in adult or geriatric diabetic condition, the growth of this segment is expected to rise during the forecast period.

Based on geographical region, North America accounted for the largest market share in 2020 and Asia-Pacific is estimated to grow at the highest CAGR during forecast period.  

As per regional segmentation, North America held the largest market share in 2020. This was due to increase in healthcare infrastructure, high diabetic population, availability of funding and high-tech facilities in healthcare led to increase in availability of insulin delivery devices. 

Conversely, Asia-Pacific is estimated to grow with highest CAGR during the forecast period. Asia-Pacific is considered to be one of the fastest growing country. Developing countries like India and China is projected to witness the highest growth due to emerging economies, government facilities and initiatives, developing technologies, and entry of new players in the market.

Company Profiles and Competitive Intelligence: Some of the key players operating in the market are Dickinson and Company (U.S.), Biocon Ltd. (India), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Animas Corporation (U.S.), Medtronic plc., Betcon, Tandem Diabetes Care, Inc. (U.S.), Sanofi (France), Eli Lilly and Company (U.S.), and Insulet Corporation (U.S.)

The report also provides in-depth analysis of the insulin delivery devices market dynamics such as drivers, restraints opportunities and challenges


  1. High diabetic population across the world
  2. Growing Awareness about Self-administering Insulin Delivery Devices


  1. Stringent Government Rules and Regulation for Product Approvals
  2. High Insulin Analogs Cost


  1. Technological Advancements and Use of Artificial Intelligence in Medical Device Sector


  1. High Cost of Insulin Devices
  2. Emergence of New Insulin Devices into the Market

COVID-19 Impact on the Insulin Delivery Devices Market Analysis

Covid-19 has highly affected the industries in terms of growth, economy, health and mental wellbeing of every individual. In this challenging situation, every industry is trying to give best services in terms of quality and safety. In case of diabetes, diabetic patients were at high risk of getting infected. Hence, they required high preventive measures and medication for preventing themselves. Along with medication, the sales of medical devices, insulins, insulin pens, pumps witnessed high growth. Due to the daily requirement of insulin and diabetes related medicines, patients use to stock-up the medications for safety, as there were restrictions on movement and travelling. This resulted in increase in market revenue of insulin delivery devices market. The demand for diabetes related medications expected to persist the pandemic situation, thereby stimulating the growth of the market.

The report also provides in-depth analysis of key trends in insulin delivery device market

Sr. No. Trends Impact
1 Due to Covid-19, there was increase in stocking up of medicines related to diabetes  Positive
2 Increase in advanced technology, rise incidences of diabetes among population  Positive
3 The funding required for research and development activities related to insulin delivery devices was reduced  Negative

The report also provides in-depth analysis of recent news developments and investments

  • In 2021, Massachusetts-based Insulet Corp. is expected to launch new technology device named ‘Omnipod 5’ also known as Omnipod Horizon. This is based on artificial pancreas technology which allows to monitor insulin dosing through tubeless patch pump via smart algorithm.
  • In January 2020, Novo Nordisk announced the approval from FDA for the use of ‘Fiasp’ -fast acting insulin delivery for children.
  • In September 2019, Medtronic plc. received an approval for the use of Envision Pro Continuous Glucose Monitoring systems in Europe and Middle east markets.
  • In February 2018, Sanofi launched new diabetes treatment called ‘Toujeo’ insulin in India. It is long acting basal analog insulin which helps to increase glycaemic levels in body.

Insuline Delivery Devices Market Company Profiles and Competitive Intelligence

The key players operating in the insuline delivery devices market are:

The unique insights provided by this report also includes the following:

  • In-depth value chain analysis
  • Opportunity mapping
  • Sector snapshot
  • Key Players Positioning Matrix
  • Regulatory scenario
  • Strategies Adopted-Benchmarking Heat Map
  • Market trends
  • Covid-19 impact analysis
  • Product comparison
  • Pre & Post COVID 19 impacts on Insulin Delivery Devices Market
  • Competitive Landscape

Frequently Asked Questions (FAQs)

The global insulin delivery device market was valued at US $ 14.3 Bn in 2020 and is anticipated to reach US$ 25.4 Bn by 2027.

The insulin delivery device market is estimated to grow at a compound annual growth rate (CAGR) of 8.7% during 2020-2027.

In the base year 2020, Asia-Pacific accounted for about more than 15% share in the insulin delivery device market.

Few key players include, but not limit up to: Dickinson and Company (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Betcon, Animas Corporation (U.S.), Medtronic plc., Tandem Diabetes Care, Inc. (U.S.), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (U.S.), and Insulet Corporation (U.S.).

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

    1. Product Outline
    2. What is Insulin Delivery Devices
    3. Different Types of Insulin Delivery Device
    4. Supply Chain Analysis
    5. Covid -19 Impact
    6. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
    7. Technology Overview
  2. Regulatory Landscape for Insulin Delivery Device
    1. Regulations and Standards
  3. Insulin Delivery Device Market by Products
    1. Insulin Pens
    2. Insulin Syringes
    3. Insulin Injectors
    4.  Insulin Pumps
  4. Insulin Delivery Device Market by End user
    1. Hospitals & Clinics
    2. Patients/Home Care
  5. Regional Analysis
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France 
      4. Spain
      5. Netherlands
      6. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Australia
      5. Rest Of Asia Pacific
    4. Middle East and Africa
    5. Latin America
  6. Key Strategic Insights
    1. New Applications
    2. Emerging Technologies
    3. Opportunity Mapping
    4. Critical Success Factors
    5. Environmental Impact and Sustainability Issues
    6. Consumer Preferences
  7. Key Market Trends / Recent Developments
  8. Competitive Scenario
    1.  Mergers and Acquisitions
    2. Investments
    3. Joint Ventures
    4. New Product launches
    5. Ranking of Key Players
    6. Presence of Players by Geographies
    1. Becton Dickinson and Company
    2.  Novo Nordisk A/S
    3.  Ypsomed Holding AG
    4. Animas Corporation
    5.  Medtronic plc.
    6. Tandem Diabetes Care, Inc.
    7.  Sanofi
    8.  Biocon Ltd.
    9.  Eli Lilly and Company

Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization